Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.
This review summarizes ALK-directed vaccines, CAR-T and other cellular therapies, and antibody-based approaches for pediatric ALK-positive tumors, citing endogenous ALK-specific immune responses and preclinical efficacy while emphasizing that clinical safety and effectiveness remain unproven.
Open original publication →What the AI sees
This review summarizes ALK-directed vaccines, CAR-T and other cellular therapies, and antibody-based approaches for pediatric ALK-positive tumors, citing endogenous ALK-specific immune responses and preclinical efficacy while emphasizing that clinical safety and effectiveness remain unproven.
Research significance
Evidence in the supplied abstract indicates that ALK is a tumor driver and oncoantigen, with spontaneous ALK-specific immune responses in patients and efficacy of ALK-directed immunotherapies in preclinical models; it is therefore inferred—not clinically established—that these approaches could complement ALK inhibitors, address resistance, and improve long-term disease control.
Source abstract
Next-Generation Treatment for Pediatric Cancer: Advancing Immunotherapy through Combinations. Cancer remains one of the leading causes of disease-related mortality among children and adolescents. Despite advances in treatments, outcomes for many pediatric tumors remain limited, particularly in patients with high-risk, relapsed, or refractory disease. Standard therapies, including surgery, chemotherapy, radiotherapy, and stem cell transplantation, are frequently associated with severe long-term toxicities and secondary malignancies. Resistance and relapse remain major clinical challenges. Recent progress in cancer immunotherapy has revolutionized adult oncology, and remarkable clinical advances have been observed in several pediatric cancers. However, comparable benefits in most solid tumors remain limited. Among molecular targets, anaplastic lymphoma kinase (ALK) has emerged as a critical driver of tumorigenesis in several pediatric malignancies, including anaplastic large cell lymphoma (ALCL), neuroblastoma and inflammatory myofibroblastic tumor. While ALK tyrosine kinase inhibitors have demonstrated clinical benefit, the emergence of resistance highlights the need for alternative or complementary strategies. ALK can act as an oncoantigen, as shown by spontaneous ALK-specific humoral and T-cell responses in patients with ALK-positive ALCL, and ALK-directed immunotherapies have been developed and have shown efficacy in preclinical models of ALK-positive tumors, including ALCL and neuroblastoma. Therefore, ALK-directed immunotherapies represent biologically rational and promising approaches that may, if proven safe and effective in clinical trials, address resistance and improve long-term disease control. In this review, we will discuss ALK-specific immunotherapies, including ALK vaccines, ALK CAR-T and other cellular therapies, as well as ALK-targeting antibodies with a particular focus on pediatric ALK-positive tumors.